According to filings with the U.S. Securities and Exchange Commission, SiVEC Biotechnologies is raising up to $5,800,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About SiVEC Biotechnologies
SiVEC Biotechnologies is a biopharmaceutical company focused on revolutionizing drug and vaccine delivery through its proprietary BactPac live biotherapeutic delivery platform. This innovative platform utilizes specialized, non-pathogenic bacteria engineered to safely and precisely deliver various therapeutic payloads, including mRNA, siRNA, proteins/nanobodies, and CRISPR/Cas, to targeted tissues, particularly mucosal epithelial cells. The company aims to overcome the limitations of traditional delivery systems like viral vectors and lipid nanoparticles, enabling unparalleled therapeutic precision and improved patient outcomes. SiVEC Biotechnologies was recognized as the 2022 Top Emerging Company by BIO International and has secured nearly $4 million in non-dilutive funding from institutions like the National Institutes of Health and the State of Colorado. Their mission is to advance nucleic acid and gene editing therapies into clinical stages by out-licensing their BactPac platform to pharmaceutical companies.

To learn more about SiVEC Biotechnologies, visit https://www.sivecbiotechnologies.com/
SiVEC Biotechnologies Linkedin Page: https://www.linkedin.com/search/results/companies/?keywords=SiVEC%20Biotechnologies

Contact:
Lyndsey Linke, Chief Executive Officer
970-310-7967

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.